You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

Patent: 10,377,832


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,377,832
Title:Modified glycoproteins
Abstract: Modified glycoproteins, and methods of making and using such modified glycoproteins, are described.
Inventor(s): Washburn; Nathaniel (Littleton, MA), Meador, III; James (Framingham, MA), Bosques; Carlos J. (Arlington, MA), Bulik; Dorota A. (Malden, MA), Bhatnagar; Naveen (Framingham, MA), Brown; Julia (Somerville, MA), Markowitz; Lynn (Waltham, MA), Prabbhakar; Sathya (Boxborough, MA)
Assignee: Momenta Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:15/497,057
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,377,832

Introduction

To conduct a comprehensive and critical analysis of the claims and the patent landscape of United States Patent 10,377,832, it is essential to understand the broader context of U.S. patent law, particularly Sections 101, 102, and 103 of the Patent Act. Here, we will delve into the specifics of the patent, the legal framework governing it, and the implications of recent judicial and administrative developments.

Understanding the Patent Act Sections

Section 101: Patent-Eligible Subject Matter

Section 101 of the Patent Act defines what constitutes patentable subject matter. It includes "any new and useful process, machine, manufacture, or composition of matter"[1][3].

Section 102: Novelty

Section 102 deals with the novelty requirement, ensuring that the invention is new and not obvious from prior art. This section is crucial in determining whether an invention qualifies for patent protection[3].

Section 103: Non-Obviousness

Section 103 addresses the non-obviousness requirement, mandating that the invention must be significantly different from existing technology to be patentable. This involves a detailed analysis of prior art to establish the invention's uniqueness[3].

The Alice/Mayo Framework

The Supreme Court's decisions in cases like Bilski v. Kappos, Mayo Collaborative Servs. v. Prometheus Labs., Association for Molecular Pathology v. Myriad Genetics, and Alice Corp. Pty. v. CLS Bank have significantly narrowed the scope of patent-eligible subject matter. The Alice/Mayo test is a two-step process:

  • Step 1: Determine if the patent claims are directed to an ineligible concept (e.g., abstract ideas, laws of nature, natural phenomena).
  • Step 2: If the claims are directed to an ineligible concept, assess whether they contain an inventive concept that transforms the nature of the claim into a patent-eligible application[1].

Patent 10,377,832: Specific Analysis

Patent Overview

Without specific details on the patent 10,377,832, we can't analyze its claims directly. However, we can discuss how to approach such an analysis.

Claim Analysis

To analyze the claims of any patent, including 10,377,832, you would need to:

  • Determine Patent-Eligible Subject Matter: Ensure the claims fall within the categories defined by Section 101. Use the Alice/Mayo framework to check if the claims are directed to an ineligible concept and if they contain an inventive concept[1][3].
  • Assess Novelty: Compare the claims against prior art to ensure the invention meets the novelty requirement under Section 102. This involves conducting a thorough prior art search and analysis[3].
  • Evaluate Non-Obviousness: Determine if the invention is non-obvious by comparing it to existing technology and assessing whether it represents a significant improvement or innovation under Section 103[3].

Practical Insights

  • Strategic Claim Drafting: Ensure that the claims are broad enough to offer substantial protection but specific enough to circumvent prior art. Highlight the unique aspects of the invention that render it eligible, novel, and non-obvious[3].
  • Effective Argumentation: Build compelling arguments around eligibility, novelty, and non-obviousness. Explain the technological advancements brought about by the invention and distinguish it clearly from the existing state of the art[3].

Recent Developments and Guidance

USPTO Guidance

The USPTO issued new guidance in 2019 to clarify how to apply the Alice/Mayo framework, which has been incorporated into the Manual of Patent Examining Procedure. This guidance has been seen as lowering Section 101 barriers to patentability, especially for computer-related inventions. However, it is not binding on courts when issued patents are challenged in litigation[1].

Legislative Proposals

Proposals like the Patent Eligibility Restoration Act (PERA) 2023 aim to redefine what constitutes modified natural material, potentially allowing for the patenting of isolated DNA segments under certain conditions. This could have significant implications for biotechnology and other fields[1].

Impact on Innovation

Encouraging Innovation

The patent system is designed to encourage innovation by providing exclusive rights to inventors. However, the narrowing of patent-eligible subject matter has raised concerns about the system's ability to incentivize investment in emerging technologies like AI and biotechnology[1].

Stakeholder Views

Stakeholders have varying views on the impact of the Alice/Mayo framework. Some argue it has negatively affected the patent system's ability to encourage innovation, while others see it as necessary to prevent the patenting of abstract ideas and natural phenomena[1].

Examples and Statistics

  • Increasing Patent Applications: The number of patent applications has been increasing significantly, driven by technological innovation. For example, from 1963 to 1983, approximately 100,000 patent applications were filed annually, whereas in 2001, 326,508 applications were filed[2].
  • Complexity of Claims: The complexity of patent claims is also increasing, with some applications containing thousands of claims. This complexity necessitates automated systems to facilitate the review process[2].

Key Takeaways

  • Patent-Eligible Subject Matter: Ensure that the invention falls within the categories defined by Section 101 and passes the Alice/Mayo test.
  • Novelty and Non-Obviousness: Conduct thorough prior art searches and analyses to establish novelty and non-obviousness under Sections 102 and 103.
  • Strategic Claim Drafting: Craft claims that are broad yet specific to offer substantial protection while circumventing prior art.
  • USPTO Guidance: Be aware of the 2019 USPTO guidance and its implications for patent eligibility.
  • Legislative Developments: Monitor legislative proposals that could alter the landscape of patent-eligible subject matter.

FAQs

Q: What are the main categories of patentable inventions under Section 101 of the Patent Act? A: Section 101 defines patentable inventions as any new and useful process, machine, manufacture, or composition of matter[1][3].

Q: How does the Alice/Mayo framework affect patent eligibility? A: The Alice/Mayo framework is a two-step test that determines if patent claims are directed to an ineligible concept and if they contain an inventive concept that transforms the nature of the claim[1].

Q: What is the impact of the 2019 USPTO guidance on patent applications? A: The 2019 USPTO guidance has been seen as lowering Section 101 barriers to patentability, especially for computer-related inventions, leading to an increase in the allowance rate for AI-related patent applications[1].

Q: How do legislative proposals like PERA 2023 affect patent eligibility? A: Proposals like PERA 2023 aim to redefine what constitutes modified natural material, potentially allowing for the patenting of isolated DNA segments under certain conditions[1].

Q: Why is it important to conduct thorough prior art searches and analyses? A: Conducting thorough prior art searches and analyses is essential to establish novelty and non-obviousness under Sections 102 and 103 of the Patent Act[3].

Sources

  1. Patent-Eligible Subject Matter Reform: An Overview - CRS Reports
  2. US20110138338A1 - Patent Claims Analysis System and Method
  3. Exploring Sections 101, 102, & 103 of U.S. Patent Law - TT Consultants
  4. Patent Landscape Report - Agrifood - WIPO
  5. Intellectual Property: Patent Office Should Define Quality, Reassess ... - GAO

More… ↓

⤷  Try for Free

Details for Patent 10,377,832

ApplicantTradenameBiologic IngredientDosage FormBLAApproval DatePatent No.Expiredate
Janssen Biotech, Inc. REOPRO abciximab Injection 103575 December 22, 1994 ⤷  Try for Free 2032-04-25
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 ⤷  Try for Free 2032-04-25
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 December 10, 1997 ⤷  Try for Free 2032-04-25
Novartis Pharmaceuticals Corporation SIMULECT basiliximab For Injection 103764 May 12, 1998 ⤷  Try for Free 2032-04-25
>Applicant>Tradename>Biologic Ingredient>Dosage Form>BLA>Approval Date>Patent No.>Expiredate
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.